Outpatient tricuspid regurgitation in the community: Clinical context and outcome.

Clinical context Community Outcome Tricuspid regurgitation

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
14 Oct 2023
Historique:
received: 10 06 2023
revised: 27 09 2023
accepted: 12 10 2023
pubmed: 17 10 2023
medline: 17 10 2023
entrez: 16 10 2023
Statut: aheadofprint

Résumé

Epidemiology of tricuspid regurgitation (TR) is poorly known and its burden in the community is challenging to define. We aimed to evaluate the prevalence of TR in a geographically defined area and its outcome, in particular overall survival and hospitalization, considering different clinical contexts. We retrospectively analyzed consecutive outpatients referred between 2006 and 2013 for echocardiography and clinical evaluation. Patients with at least moderate TR were included and five different clinical settings were defined: concomitant significant left-sided valvular heart disease (LVHD-TR), heart failure (HF-TR), previous open-heart valvular surgery (postop-TR), pulmonary hypertension (PHTN-TR) and isolated TR (isolated-TR). Primary endpoint was a composite outcome of all-cause mortality or first hospitalization for HF. Of 6797 consecutive patients with a clinical visit and echocardiograms performed in routine practice in a geographically defined community, moderate or severe TR was found in 4.8% of patients (327) . During median follow-up of 6.1 years, TR severity was a determinant of event-free survival. Analyzed for each clinical subset, eight-year event-free survival was 87 ± 7% for postop-TR subgroup, 75 ± 7% for isolated-TR, 67 ± 6% for PHTN-TR, 58 ± 6% for LHVD -TR and 52 ± 11% for HF-TR. Moderate or more TR is a notable finding in the community and has impact on event-free survival in all clinical settings, with the worst outcomes when associated with relevant left-sided valvular heart disease and HF.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Epidemiology of tricuspid regurgitation (TR) is poorly known and its burden in the community is challenging to define. We aimed to evaluate the prevalence of TR in a geographically defined area and its outcome, in particular overall survival and hospitalization, considering different clinical contexts.
METHODS METHODS
We retrospectively analyzed consecutive outpatients referred between 2006 and 2013 for echocardiography and clinical evaluation. Patients with at least moderate TR were included and five different clinical settings were defined: concomitant significant left-sided valvular heart disease (LVHD-TR), heart failure (HF-TR), previous open-heart valvular surgery (postop-TR), pulmonary hypertension (PHTN-TR) and isolated TR (isolated-TR). Primary endpoint was a composite outcome of all-cause mortality or first hospitalization for HF.
RESULTS RESULTS
Of 6797 consecutive patients with a clinical visit and echocardiograms performed in routine practice in a geographically defined community, moderate or severe TR was found in 4.8% of patients (327) . During median follow-up of 6.1 years, TR severity was a determinant of event-free survival. Analyzed for each clinical subset, eight-year event-free survival was 87 ± 7% for postop-TR subgroup, 75 ± 7% for isolated-TR, 67 ± 6% for PHTN-TR, 58 ± 6% for LHVD -TR and 52 ± 11% for HF-TR.
CONCLUSION CONCLUSIONS
Moderate or more TR is a notable finding in the community and has impact on event-free survival in all clinical settings, with the worst outcomes when associated with relevant left-sided valvular heart disease and HF.

Identifiants

pubmed: 37844668
pii: S0167-5273(23)01505-X
doi: 10.1016/j.ijcard.2023.131443
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131443

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interest.

Auteurs

Denis Leonardi (D)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Francesca Bursi (F)

Division of Cardiology, Heart and Lung Department, San Paolo Hospital, ASST Santi Paolo and Carlo, University of Milan, Milan, Italy.

Diego Fanti (D)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Alberto Dotto (A)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Luca Ciceri (L)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Paolo Springhetti (P)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Corinna Bergamini (C)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Elvin Tafciu (E)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Caterina Maffeis (C)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Roberto Scarsini (R)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Maurice Enriquez-Sarano (M)

Minneapolis Heart Institute Foundation and the Valve Science Center, Minneapolis, MN, USA.

Flavio Luciano Ribichini (FL)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Giovanni Benfari (G)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy. Electronic address: giovanni.benfari@univr.it.

Classifications MeSH